Nigel S Cook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1538567/publications.pdf

Version: 2024-02-01

687363 501196 1,430 29 13 28 h-index citations g-index papers 29 29 29 719 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study. ERJ Open Research, 2022, 8, 00686-2021.	2.6	3
2	Development of an international template to support patient submissions in Health Technology Assessments. International Journal of Technology Assessment in Health Care, 2021, 37, e50.	0.5	3
3	How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations. International Journal of Technology Assessment in Health Care, 2021, 37, .	0.5	7
4	Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice. Advances in Therapy, 2020, 37, 17-26.	2.9	15
5	Patient Preferences in the Medical Product Lifecycle. Patient, 2020, 13, 7-10.	2.7	8
6	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis. JHEP Reports, 2020, 2, 100081.	4.9	4
7	Identification of Patient Needs and Preferences in Pigmented Villonodular Synovitis (PVNS) Using a Qualitative Online Bulletin Board Study. Advances in Therapy, 2020, 37, 2813-2828.	2.9	2
8	Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community. International Journal of COPD, 2019, Volume 14, 1365-1376.	2.3	14
9	Evaluating Patient Experiences in Dry Eye Disease Through Social Media Listening Research. Ophthalmology and Therapy, 2019, 8, 407-420.	2.3	39
10	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. Frontiers in Medicine, 2019, 6, 61.	2.6	26
11	Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs. Frontiers in Medicine, 2019, 6, 82.	2.6	31
12	Patient Needs, Perceptions, and Attitudinal Drivers Associated with Obesity: A Qualitative Online Bulletin Board Study. Advances in Therapy, 2019, 36, 842-857.	2.9	8
13	Patients' perspectives on COPD: findings from a social media listening study. ERJ Open Research, 2019, 5, 00128-2018.	2.6	37
14	Defining the needs and preferences of patients with dry eye disease. BMJ Open Ophthalmology, 2019, 4, e000315.	1.6	9
15	Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries. BMJ Open Ophthalmology, 2019, 4, e000360.	1.6	11
16	Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study. Advances in Therapy, 2019, 36, 478-491.	2.9	29
17	PP47 Defining The Needs And Preferences Of Patients With Dry Eye Disease. International Journal of Technology Assessment in Health Care, 2018, 34, 83-84.	0.5	2
18	The Role of Patients inMarket Access. , 2018, , 267-288.		3

#	Article	lF	CITATION
19	Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public–Private Project. Patient, 2017, 10, 263-266.	2.7	96
20	VP161 Identification Of Needs Of Pigmented Villonodular Synovitis Patients Using Online Bulletin Board. International Journal of Technology Assessment in Health Care, 2017, 33, 222-223.	0.5	3
21	Beta-amino acid derivatives as orally active non-peptide fibrinogen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 727-732.	2.2	16
22	Inhibition of platelet GPIIbIa in an ex vivo model of hyperacute xenograft rejection does not prolong cardiac survival time. Xenotransplantation, 1996, 3, 43-52.	2.8	13
23	Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma. Cardiovascular Drugs and Therapy, 1993, 7, 555-563.	2.6	19
24	The Effects of Two Synthetic Glycoprotein II b/III a Antagonists, Ro 43-8857 and L-700,462, on Platelet Aggregation and Bleeding in Guinea-Pigs and Dogs: Evidence that Ro 43-8857 Is Orally Active. Thrombosis and Haemostasis, 1993, 70, 838-847.	3.4	34
25	Moving together: K+ channel openersand ATP-sensitive K+ channels. Trends in Pharmacological Sciences, 1989, 10, 431-435.	8.7	289
26	PN 200?110, a Calcium Antagonist with High Potency and Selectivity for Vascular Smooth Muscle. Annals of the New York Academy of Sciences, 1988, 522, 304-305.	3.8	6
27	The pharmacology of potassium channels and their therapeutic potential. Trends in Pharmacological Sciences, 1988, 9, 21-28.	8.7	568
28	Cardiovascular effects of apamin and BRL 34915 in rats and rabbits. British Journal of Pharmacology, 1988, 93, 121-131.	5.4	49
29	Antiâ€vasoconstrictor effects of the K ⁺ channel opener cromakalim on the rabbit aorta—comparison with the calcium antagonist isradipine. British Journal of Pharmacology, 1988, 95, 741-752.	5.4	86